159 related articles for article (PubMed ID: 34374649)
1. Shrinkage by the third month predicts long-term response of macroprolactinoma after cabergoline.
Biagetti B; Sarria-Estrada S; Ng-Wong YK; Martinez-Saez E; Casteràs A; Cordero Asanza E; Hernandez I; Giralt-Arnaiz M; Simò R
Eur J Endocrinol; 2021 Sep; 185(4):587-595. PubMed ID: 34374649
[TBL] [Abstract][Full Text] [Related]
2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
3. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
4. Predictors of Chronic LH-Testosterone Axis Suppression in Male Macroprolactinomas With Normoprolactinemia on Cabergoline.
Sehemby M; Lila AR; Sarathi V; Shah R; Sankhe S; Jaiswal SK; Ramteke-Jadhav S; Patil V; Shah N; Bandgar T
J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32942295
[TBL] [Abstract][Full Text] [Related]
5. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
6. Treatment of multiresistant prolactinomas with a combination of cabergoline and octreotide LAR.
Sosa-Eroza E; Espinosa E; Ramírez-Rentería C; Mendoza V; Arreola R; Mercado M
Endocrine; 2018 Aug; 61(2):343-348. PubMed ID: 29948930
[TBL] [Abstract][Full Text] [Related]
7. Biochemical Remission after Cabergoline Withdrawal in Hyperprolactinemic Patients with Visible Remnant Pituitary Adenoma.
Kim K; Park YW; Kim D; Ahn SS; Moon JH; Kim EH; Lee EJ; Ku CR
J Clin Endocrinol Metab; 2021 Jan; 106(2):e615-e624. PubMed ID: 33079168
[TBL] [Abstract][Full Text] [Related]
8. Giant prolactinomas: are they really different from ordinary macroprolactinomas?
Espinosa E; Sosa E; Mendoza V; Ramírez C; Melgar V; Mercado M
Endocrine; 2016 Jun; 52(3):652-9. PubMed ID: 26561015
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
10. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
[TBL] [Abstract][Full Text] [Related]
11. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
[TBL] [Abstract][Full Text] [Related]
13. Prolactin ≤1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy.
Kim D; Ku CR; Kim K; Jung H; Lee EJ
Eur J Endocrinol; 2020 Feb; 182(2):177-183. PubMed ID: 31770105
[TBL] [Abstract][Full Text] [Related]
14. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
15. Cabergoline as a first-line treatment in newly diagnosed macroprolactinomas.
Pontikides N; Krassas GE; Nikopoulou E; Kaltsas T
Pituitary; 2000 May; 2(4):277-81. PubMed ID: 11081149
[TBL] [Abstract][Full Text] [Related]
16. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
17. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
Kars M; Pereira AM; Smit JW; Romijn JA
Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
[TBL] [Abstract][Full Text] [Related]
19. Brain and optic chiasmal herniation following cabergoline treatment for a giant prolactinoma: wait or intervene?
Papanastasiou L; Fountoulakis S; Pappa T; Liberopoulos K; Malliopoulos D; Markou A; Piaditis G
Hormones (Athens); 2014; 13(2):290-5. PubMed ID: 24776630
[TBL] [Abstract][Full Text] [Related]
20. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
